Tier 2 — strong

Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study

Italo Corsale, Paolo Carrieri, Jacopo Martellucci, Alessandro Piccolomini, Luigi Verre, Marco Rigutini, Sonia Panicucci
International journal of colorectal disease 2018 33(11):1595

Bibliography

PubMed
PMID 29934701
DOI
10.1007/s00384-018-3102-y
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind active-comparator flavonoid trial
ModelHuman intervention research
Sample154 adults with hemorrhoidal disease; 78 and 76 per group
InterventionFive-flavonoid mixture including quercetin versus another flavonoid mixture
Duration1- and 6-month assessments
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2018, this source examined inflammation and clinical symptoms. Design: Randomized double-blind active-comparator flavonoid trial. Sample/model: 154 adults with hemorrhoidal disease; 78 and 76 per group. The exposure or intervention was Five-flavonoid mixture including quercetin versus another flavonoid mixture. Follow-up or treatment period: 1- and 6-month assessments.

Bleeding improved similarly in both groups. Satisfaction favored the quercetin-containing mixture at 6 months.

Several active ingredients and an active comparator. No quercetin-specific bleeding benefit was demonstrated.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Bleeding improved similarly in both groups.
  • Satisfaction favored the quercetin-containing mixture at 6 months.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Five-flavonoid mixture including quercetin versus another flavonoid mixture; 1- and 6-month assessments.

What this study can and cannot tell us

  • Several active ingredients and an active comparator. No quercetin-specific bleeding benefit was demonstrated.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study
Eman Mohamed Elmokadem et al. · Drug design, development and therapy · 2025
Tier 2
The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial
Zohreh Sajadi Hezaveh et al. · Complementary therapies in medicine · 2019
Tier 2
The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial
Fatemeh Javadi et al. · Journal of the American College of Nutrition · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology